Skip to main content

Advertisement

Table 3 Discontinuations (several reasons could be given in parallel

From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

  Etanercept Tocilizumab Interleukin-1 inhibitor
Discontinuations 77 (53.8%) 28 (39.4%) 28 (46.7%)
Inefficacy 62 (43.4%) 6 (8.5%) 13 (21.7%)
Intolerance 5 (3.5%) 14 (19.7%) 1 (1.7)
Remission 0 18 (25.4%) 11 (18.3)
Othersa 15 (10.5%) 3 (4.2%) 3 (5.0%)
  1. aOther reasons: in the etanercept cohort, patient’s/parent’s wish (n = 6); no further visits by the patient (n = 2), treatment with approved biologic available (n = 2), no restart after an adverse event although it disappeared (n = 2), reason not reported (n = 3); in patients on anakinra, a patient was admitted to a clinical trial (n = 1), reason not reported (n = 2); in patients on tocilizumab, reason not reported (n = 3)